Introduction of a Simplified Psoriatic Arthritis Magnetic Resonance Imaging Score (sPsAMRIS): A Potential Tool for Treatment Monitoring in Peripheral Psoriatic Arthritis.
OMERACT
PsAMRIS
magnetic resonance imaging
psoriatic arthritis
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
15 Dec 2020
15 Dec 2020
Historique:
received:
17
11
2020
revised:
12
12
2020
accepted:
14
12
2020
entrez:
18
12
2020
pubmed:
19
12
2020
medline:
19
12
2020
Statut:
epublish
Résumé
To evaluate whether a simplified (s) version of the psoriatic arthritis magnetic resonance imaging score (PsAMRIS), sPsAMRIS, is a potential tool for therapy monitoring in psoriatic arthritis (PsA). Seventeen patients with active psoriatic arthritis (PsA) underwent magnetic resonance imaging (MRI) at 3 T of the clinically dominant hand at baseline and after 6 months. Scoring was performed by two musculoskeletal radiologists in terms of the PsAMRIS and sPsAMRIS, which is a simplified version with reduced item numbers based on prior evaluation of responsiveness to change by standardized response means (SRMs). Both scores were compared by calculation of overall and each sub-score's SRMs and relative efficacy (RE) after bootstrapping. PsAMRIS sub-scores of MCP joints 3 and 4, and proximal interphalangeal (PIP) joint 4 had the highest SRM (-0.07 each), indicating highest responsiveness to change, and were, therefore, included in sPsAMRIS. Compared to PsAMRIS, sPsAMRIS was characterized by higher SRMs (sPsAMRIS: -0.13 vs. PsAMRIS: -0.02) and higher RE (29.46). sPsAMRIS and PsAMRIS were highly correlated at baseline (r = 0.75, Due to its similar responsiveness to change compared to standard PsAMRIS, and time efficiency, sPsAMRIS might be a potential diagnostic tool to quantitatively assess and monitor therapy in PsA.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate whether a simplified (s) version of the psoriatic arthritis magnetic resonance imaging score (PsAMRIS), sPsAMRIS, is a potential tool for therapy monitoring in psoriatic arthritis (PsA).
METHODS
METHODS
Seventeen patients with active psoriatic arthritis (PsA) underwent magnetic resonance imaging (MRI) at 3 T of the clinically dominant hand at baseline and after 6 months. Scoring was performed by two musculoskeletal radiologists in terms of the PsAMRIS and sPsAMRIS, which is a simplified version with reduced item numbers based on prior evaluation of responsiveness to change by standardized response means (SRMs). Both scores were compared by calculation of overall and each sub-score's SRMs and relative efficacy (RE) after bootstrapping.
RESULTS
RESULTS
PsAMRIS sub-scores of MCP joints 3 and 4, and proximal interphalangeal (PIP) joint 4 had the highest SRM (-0.07 each), indicating highest responsiveness to change, and were, therefore, included in sPsAMRIS. Compared to PsAMRIS, sPsAMRIS was characterized by higher SRMs (sPsAMRIS: -0.13 vs. PsAMRIS: -0.02) and higher RE (29.46). sPsAMRIS and PsAMRIS were highly correlated at baseline (r = 0.75,
CONCLUSION
CONCLUSIONS
Due to its similar responsiveness to change compared to standard PsAMRIS, and time efficiency, sPsAMRIS might be a potential diagnostic tool to quantitatively assess and monitor therapy in PsA.
Identifiants
pubmed: 33333853
pii: diagnostics10121093
doi: 10.3390/diagnostics10121093
pmc: PMC7765290
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf
ID : none
Organisme : Deutsche Forschungsgemeinschaft
ID : NE 2136/3-1
Organisme : Pfizer Health Research Foundation
ID : Pfizer GIP Inflammation Germany Research Initiative
Organisme : Bundesministerium für Bildung und Forschung
ID : 01EC1009
Références
J Dermatol. 2015 Dec;42(12):1153-9
pubmed: 26109492
Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S66-9
pubmed: 26470678
J Rheumatol. 2009 Aug;36(8):1816-24
pubmed: 19671819
Ann Rheum Dis. 2015 Jan;74(1):185-9
pubmed: 25261575
Curr Pharm Des. 2018;24(3):262-280
pubmed: 29359662
Arthritis Rheum. 2006 Aug;54(8):2665-73
pubmed: 16871531
Arthritis Rheum. 2011 Apr;63(4):939-48
pubmed: 21128258
J Rheumatol. 2009 Aug;36(8):1811-5
pubmed: 19671818
Rheumatology (Oxford). 2018 Aug 1;57(8):1321-1331
pubmed: 29045698
Z Rheumatol. 2013 Oct;72(8):771-8
pubmed: 24085530
J Rheumatol. 2011 Sep;38(9):2034-8
pubmed: 21885513
PLoS One. 2015 Apr 08;10(4):e0123582
pubmed: 25853482
Postgrad Med. 2018 Jan;130(1):137-141
pubmed: 29088976
Nat Rev Rheumatol. 2016 Dec;12(12):743-750
pubmed: 27829672
Clin Exp Rheumatol. 2015 Mar-Apr;33(2):209-15
pubmed: 25664925
Ann Rheum Dis. 2018 Sep;77(9):1290-1294
pubmed: 29875096
Arthritis Res Ther. 2015 Jun 01;17:141
pubmed: 26028339
J Ultrason. 2016 Jun;16(65):163-74
pubmed: 27446601
J Rheumatol. 2007 Apr;34(4):852-3
pubmed: 17407237
Hip Pelvis. 2017 Dec;29(4):211-222
pubmed: 29250494
AJR Am J Roentgenol. 2017 Feb;208(2):W45-W53
pubmed: 27929683
J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1999-2009
pubmed: 28681405
J Rheumatol. 2015 Dec;42(12):2473-9
pubmed: 26523032
Curr Rheumatol Rep. 2015 Jun;17(6):517
pubmed: 25903668
Best Pract Res Clin Rheumatol. 2012 Dec;26(6):805-22
pubmed: 23273793
Arthritis Res Ther. 2006;8(2):207
pubmed: 16569257
J Rheumatol. 2003 Jun;30(6):1385-6
pubmed: 12784422
Isr Med Assoc J. 2017 Nov;19(11):708-711
pubmed: 29185286
Ann Rheum Dis. 2019 Feb;78(2):286-287
pubmed: 30242033
Skeletal Radiol. 2018 Feb;47(2):279-287
pubmed: 29110050